Resistance issues and community-acquired respiratory infections

World Health Organization, 2000 Kariuki, 2001, Global aspects of antimicrobial-resistant enteric bacteria, Curr Opin Infect Dis., 14, 579, 10.1097/00001432-200110000-00012 Austin, 1999, The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance, 96, 1152 Guillemot, 1998, Low dosage and long treatment duration of beta-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae, JAMA, 279, 365, 10.1001/jama.279.5.365 Andremont, 2001, The future control of bacterial resistance to antimicrobial agents, Am J Infect Control, 29, 256, 10.1067/mic.2001.115672 Ben-David, 2002, Appropriate use of antibiotics for respiratory infections: review of recent statements and position papers, Curr Opin Infect Dis, 15, 151, 10.1097/00001432-200204000-00009 Patterson, 2001, Antibiotic utilization: is there an effect on antimicrobial resistance?, Chest, 119, 426S, 10.1378/chest.119.2_suppl.426S Holmberg, 1987, Health and economic impacts of antimicrobial resistance, Rev Infect Dis, 9, 1065, 10.1093/clinids/9.6.1065 Linden, 1998, Clinical implications of nosocomial gram-positive bacteremia and superimposed antimicrobial resistance, Am J Med, 104, 24S, 10.1016/S0002-9343(98)00152-1 Niederman, 2001, Impact of antibiotic resistance on clinical outcomes and the cost of care, Crit Care Med, 29, N114, 10.1097/00003246-200104001-00011 File, 2002, Judicious use of antibiotics to treat respiratory infections, Curr Opin Infect Dis, 15, 149, 10.1097/00001432-200204000-00008 Gould, 2002, Antibiotic policies and the control of resistance, Curr Opin Infect Dis, 15, 395, 10.1097/00001432-200208000-00007 Ball, 2002, Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence, J Antimicrob Chemother, 49, 31, 10.1093/jac/49.1.31 Pflomm, 2002, Strategies for minimizing antimicrobial resistance, Am J Health-Syst Pharm, 59, S12, 10.1093/ajhp/59.suppl_3.S12 Low, 2002, The era of antimicrobial resistance—implications for the clinical laboratory, Clin Microbiol Infect, 8, 9, 10.1046/j.1469-0691.8.s.3.2.x Jones, 2001, Resistance patterns among nosocomiat pathogens: trends over the past few years, Chest, 119, 397S, 10.1378/chest.119.2_suppl.397S Jacobs, 2003, The Alexander Project 1998–2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents, J Antimicrob Chemother, 52, 229, 10.1093/jac/dkg321 Jones, 2003, Global epidemiology of antimicrobial resistance among community-acquired and nosocomial pathogens: a five-year summary from the SENTRY Antimicrobial Surveillance Program (1997–2001), Semin Respir Crit Care Med., 24, 121, 10.1055/s-2003-37923 Davies, 2003, Cross-resistance, relatedness and allele analysis of fluoroquinolone-resistant US clinical isolates of Streptococcus pneumoniae (1998–2000), J Antimicrob Chemother, 52, 168, 10.1093/jac/dkg309 Karlowsky, 2003, Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998–2002), Clin Infect Dis, 36, 936, 10.1086/374052 Thornsberry, 2002, Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999–2000, Clin Infect Dis, 34, S4, 10.1086/324525 Weaver, 2003, Rates of antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States: results from the TRUST 7 (2002–2003) Surveillance Study. Abstract 201